Indivior (NASDAQ:INDV) Lowered to “Hold” Rating by Zacks Research

Zacks Research downgraded shares of Indivior (NASDAQ:INDV) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on INDV. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Barclays initiated coverage on Indivior in a research note on Thursday, June 18th. They set an “overweight” rating and a $46.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.29.

Indivior Price Performance

Shares of Indivior stock opened at $41.03 on Monday. The business has a 50-day moving average of $37.40 and a 200-day moving average of $34.75. The company has a market capitalization of $5.00 billion, a PE ratio of 21.04 and a beta of 0.88. Indivior has a 1-year low of $14.52 and a 1-year high of $42.81.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The business had revenue of $317.00 million for the quarter. On average, equities analysts expect that Indivior will post 4.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

Institutional investors have recently made changes to their positions in the company. Oaktree Capital Management LP lifted its stake in Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after purchasing an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP increased its stake in Indivior by 2,372.5% during the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after purchasing an additional 3,226,605 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after purchasing an additional 3,201,639 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Indivior during the fourth quarter worth $82,687,000. Finally, Vanguard Group Inc. lifted its position in shares of Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after buying an additional 2,008,078 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.